Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights. Exton, Pennsylvania, Sept. 14, 2023 (GLOBE NEWSWIRE) -- This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic US immunology...